Schedule 13G ownership disclosure
Novus Therapeutics, Inc.
Security class unavailable · CUSIP: 67011N105
Event date: 2020-10-29
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 224,071
- Percent of class
- 15.7000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000935836-20-000603
- Form type
- SC 13G
- Filer
- Logos Global Management LP
- CIK
- CIK 1792126
- Filed
- Nov 09, 2020
- Reporting period
- Oct 29, 2020
- Description
- Schedule 13G beneficial ownership